No Data
No Data
MaxCyte Expands Share Capital, Fuels Cell Therapy Growth
We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth
BlackRock Ups Stake in MaxCyte to 9.75%
Craig-Hallum Maintains MaxCyte(MXCT.US) With Buy Rating
Express News | MaxCyte, Inc. MaxCyte, Inc. - Mxcr - Signing of Strategic Platform License
MaxCyte Signs Strategic Platform License With Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases